J&J pharmaceuticals, diagnostic news
Johnson & Johnson announced the creation of three dedicated groups to concentrate its R&D in disease interception, disease prevention and microbiome research. Each of the groups will collaborate with the pharma’s existing therapeutic areas -- cardiovascular and metabolism; immunology; infectious diseases and vaccines; neuroscience; and oncology -- and with external partners in industry and academia.
The Disease Interception Accelerator will research ways to predict and prevent progression to disease in at-risk populations. The group’s first research collaboration, with the juvenile diabetes advocacy group JDRF, aims to develop diagnostics, therapeutics or combination approaches intended to prevent the onset of Type I diabetes in individuals who are at risk for the disease, before clinical symptoms emerge. ...